Eli Lilly has returned to Nimbus…
Eli Lilly has returned to Nimbus Therapeutics for another metabolic [...]
A pair of phase 3 psoriasis…
A pair of phase 3 psoriasis studies of Alumis’ TYK2 [...]
Instil Bio’s hopes for its…
Instil Bio’s hopes for its refreshed clinical pipeline appear to [...]
The Centers for Disease Control…
The Centers for Disease Control and Prevention has upended the [...]
After shepherding the company…
After shepherding the company through its first approval and the [...]
Bausch + Lomb has partnered with…
Bausch + Lomb has partnered with the glaucoma community once [...]
With the result falling short of…
With the result falling short of the bar Amgen set [...]
Aktis Oncology is aiming to bring…
Aktis Oncology is aiming to bring in $182 million—or more—from [...]
Sanofi has returned to U.S….
Sanofi has returned to U.S. artificial intelligence research biotech Earendil [...]
‘Chinese Peptides’ Are the Latest Biohacking Trend in the Tech World
The gray-market drugs flooding Silicon Valley reveal a community that [...]